SCHEMBL25345830

SCHEMBL25345830

COc1ccc(-c2c[nH]nc2C)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.54
TDO2 P48775 1/20 0.49
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
MAPK1 P28482 1/20 0.44
PRKAG1 P54619 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAB1 Q9Y478 1/20 0.43
PIK3CA P42336 2/20 0.43
FYN P06241 2/20 0.42
RPS6KA3 P51812 1/20 0.42
TNIK Q9UKE5 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
KCNH2 Q12809 1/20 0.41
JAK2 O60674 1/20 0.41
NNMT P40261 1/20 0.40
ERN1 O75460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3846129 0.83 TDO2 (0.42) CYP2A6TDO2HSD17B1HSD17B2MAPK1
SCHEMBL25343737 0.79 TDO2 (0.32) CYP2A6TDO2
SCHEMBL4022386 0.78 TDO2 (0.43) TDO2MKNK1MKNK2MAPK1TNIK
SCHEMBL31174412 0.75 CYP2A6 (0.68) CYP2A6TDO2MKNK1MKNK2HSD17B1
SCHEMBL3754419 0.75 CYP2A6 (0.68) CYP2A6TDO2MKNK1MKNK2HSD17B1
SCHEMBL15984748 0.73 CYP2A6 (0.54) CYP2A6TDO2MKNK1MKNK2HSD17B1
SCHEMBL15730261 0.73 CYP2A6 (0.54) CYP2A6TDO2MKNK1MKNK2HSD17B1
SCHEMBL10094614 0.72 CYP2A6 (0.61) CYP2A6MKNK1MKNK2HSD17B1HSD17B2
SCHEMBL2419516 0.72 MEN1 (0.40)
SCHEMBL30884522 0.72 ALDH1A1 (0.52) CYP2A6TDO2MKNK1MKNK2HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4476204-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS Theras, Inc. (US) 2024-12-18 EP disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed